Investor Presentaiton

19 Corporate Sustainability and ESG at Alvotech alvotech Strong Thematic Basis Biosimilars promote the sustainability of healthcare systems by improving patient access: providing lower cost alternatives to higher priced biologics Biologics are a growing class of medicines that account for almost one third of the global market for pharmaceuticals by value(1) Limited public comps for global pure play model provides investors exposure to the social and economic benefits of biosimilars • Strong Intrinsic Qualities Scope 1 and 2 carbon neutral for 2020 and 2021 Manufacturing utilizes nearly 100% of electricity from renewable energy sources Located in Iceland which is an isolated energy system based on hydro and geothermal resources Limited water scarcity and wildfire risks Biologics are biodegradable: limits exposure to Pharmaceuticals in Environment (PIE) issues • R&D driven business model Strong Commitment to ESG о о Materiality assessment performed ESG Portal to be made available to stakeholders with metrics consistent with NASDAQ and/or GRI frameworks Key policies implemented in connection with business combination Governance, code of ethics, whistleblower, anti-harassment, and data privacy protection Annual equal pay audits, equality and diversity assessments, and employee engagement survey Joined UN Global Compact 1.IQVIA INSTITUTE; Spotlight on Biosimilars, Optimizing The Sustainability of Healthcare Systems, June 2021 - Data refers to 2021 © ALVOTECH. ALL RIGHTS RESERVED

View entire presentation